Insmed Overview

  • Year Founded
  • 1988

Year Founded

  • Status
  • Public

  • Employees
  • 1,664

Employees

  • Stock Symbol
  • INSM

Stock Symbol

  • Investments
  • 7

  • Share Price
  • $141.33
  • (As of Friday Closing)

Insmed General Information

Description

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Contact Information

Website
www.insmed.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 700 US Highway 202/206
  • Bridgewater, NJ 08807
  • United States
+1 (908)
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 700 US Highway 202/206
  • Bridgewater, NJ 08807
  • United States
+1 (908)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Insmed Stock Performance

As of 20-Nov-2026, Insmed’s stock price is $141.33. Its current market cap is $31B with 219M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$141.33 $144.46 $90.39 - $212.75 $31B 219M 3.06M -$2.82

Insmed Financials Summary

As of 30-Sep-2026, Insmed has a trailing 12-month revenue of $1.52B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 24,345,634 36,014,410 11,883,404 4,844,741
Revenue 1,519,721 606,423 363,707 305,208
EBITDA (498,129) (1,177,770) (820,936) (662,038)
Net Income (605,609) (1,276,775) (913,772) (749,567)
Total Assets 2,226,056 2,264,558 2,025,231 1,329,837
Total Debt 584,705 586,671 1,148,877 1,203,994
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Insmed Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Insmed‘s full profile, request access.

Request a free trial

Insmed Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three the
Biotechnology
Bridgewater, NJ
1,664 As of 2025

Waltham, MA
 

New York, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Insmed Competitors (90)

One of Insmed’s 90 competitors is Ardelyx, a Formerly VC-backed company based in Waltham, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ardelyx Formerly VC-backed Waltham, MA
Titan Pharmaceuticals Corporation New York, NY
Citius Pharma Formerly Angel backed Cranford, NJ
Arrowhead Pharmaceuticals Corporation Pasadena, CA
Rallybio Formerly VC-backed New Haven, CT
You’re viewing 5 of 90 competitors. Get the full list »

Insmed Patents

Insmed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026156112-A1 Dpp1 inhibitors for use in medicine Pending 16-Jan-2025
WO-2026148258-A2 Dipeptidyl peptidase 1 inhibitors and uses thereof Pending 03-Jan-2025
WO-2026148258-A3 Dipeptidyl peptidase 1 inhibitors and uses thereof Pending 03-Jan-2025
WO-2026136275-A1 Dipeptidyl peptidase 1 inhibitors and uses thereof Pending 16-Dec-2024
WO-2026107326-A1 Synthesis of brensocatib((2s)-n-((1s)-1-cyano-2-(4-(3-methyl-2-oxo-2,3 -dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide) Pending 15-Nov-2024 C07D413/12
To view Insmed’s complete patent history, request access »

Insmed Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Insmed Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Insmed‘s full profile, request access.

Request a free trial

Insmed Acquisitions (7)

Insmed’s most recent deal was a Merger/Acquisition with Opsidio for . The deal was made on 01-Dec-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Opsidio 01-Dec-2025 Merger/Acquisition Drug Discovery
Insmed Innovation 30-Jun-2023 Merger/Acquisition Drug Discovery
Vertuis Bio 06-Jan-2023 Merger/Acquisition Drug Discovery
AlgaeneX 04-Aug-2021 Merger/Acquisition Drug Discovery
Motus Biosciences 04-Aug-2021 Merger/Acquisition Discovery Tools (Healthcare)
You’re viewing 5 of 7 acquisitions. Get the full list »

Insmed ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

24.15 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Insmed’s complete esg history, request access »

Insmed Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
AlgaeneX San Diego, CA 2020

Insmed FAQs

  • When was Insmed founded?

    Insmed was founded in 1988.

  • Where is Insmed headquartered?

    Insmed is headquartered in Bridgewater, NJ.

  • What is the size of Insmed?

    Insmed has 1,664 total employees.

  • What industry is Insmed in?

    Insmed’s primary industry is Biotechnology.

  • Is Insmed a private or public company?

    Insmed is a Public company.

  • What is Insmed’s stock symbol?

    The ticker symbol for Insmed is INSM.

  • What is the current stock price of Insmed?

    As of 20-Nov-2026 the stock price of Insmed is $141.33.

  • What is the current market cap of Insmed?

    The current market capitalization of Insmed is $31B.

  • What is Insmed’s current revenue?

    The trailing twelve month revenue for Insmed is $1.52B.

  • Who are Insmed’s competitors?

    Ardelyx, Titan Pharmaceuticals, Citius Pharma, Arrowhead Pharmaceuticals, and Rallybio are some of the 90 competitors of Insmed.

  • What is Insmed’s annual earnings per share (EPS)?

    Insmed’s EPS for 12 months was -$2.82.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process